Clostridium difficile infection (CDI) has become a major emerging cause of morbidity and mortality among hospitalized patients since the epidemics of hypervirulent and antibiotic-resistant strains began in the early 2000s. It is therefore important to develop new preventions/treatments to counteract the rapid increase in the incidence of CDI. While standard treatments with antibiotics are not effective resulting in high rates of relapse, animal and clinical studies have unambiguously demonstrated that antitoxin antibodies are protective against both primary and recurrent CDI. Our goal is to develop novel immunoprophylaxes against both primary and recurrent CDI in aged high-risk populations. In this proposal we aim to exploit two novel compounds (ABBA and cTxAB) developed in this lab: 1) ABBA is a single tetra-specific binding agent consisting of four distinct neutralizing VHH monomers (two against TcdA and two against TcdB);and 2) cTxAB is an atoxic, clostridial toxin-like chimeric vaccine for which a product development plan (PDP) toward clinical trials is currently being developed under NIH funding. We have already demonstrated potent efficacy of ABBA against fulminant CDI in mice. We will further optimize and finalize its delivery strategies in this project. To reduce potential immunogenicity and increase the serum half-life of ABBA for systemic administration, we will generate ABBA-Fc fusions and humanized ABBA-lgGIs without compromising its superior affinity to toxins and neutralizing activity. In addition, we will develop a colonic delivery system for intestinal delivery of ABBA. The lead compounds generated for systemic and oral deliveries will be evaluated in a hamster fulminant CDI model as well as in gnotobiotic piglets colonized with human intestinal flora. Moreover, we will combine the passive ABBA immunization with active cTxAB vaccination and evaluate protection against both primary and recurrent CDI in relevant immunosenescent mouse models. Our ultimate goal is to develop novel immunoprophylaxes and combinations of active and passive immunizations that we wish to prevent against both immediate and longer term CDI threats in aged patients with high risk of developing this debilitating disease. This project will help to achieve the broad objective ofthe entire CETR proposal and to address the hypothesis that we can translate promising immunoprophylactic candidate products being tested in relevant immunosenescent animal models into immune preventions against important enteric pathogens for which the ultimate human targets are elderly subjects.
Clostridium difficile infection (CDI) is a major emerging cause of morbidity and mortality among hospitalized elderly patients. This project will optimize and finalize delivery strategies for a potent multi-specific antibody developed in this lab and combine passive and active immunizations in order to prevent both immediate and longer term CDI threats in aged patients with high risk of developing this debilitating disease.
|Higginson, Ellen E; Simon, Raphael; Tennant, Sharon M (2016) Animal Models for Salmonellosis: Applications in Vaccine Research. Clin Vaccine Immunol 23:746-56|
|Curtis, Brittany; Grassel, Christen; Laufer, Rachel S et al. (2016) Simple method for purification of enterotoxigenic Escherichia coli fimbriae. Protein Expr Purif 119:130-5|
|Tennant, Sharon M; Steele, A Duncan; Pasetti, Marcela F (2016) Highlights of the 8th International Conference on Vaccines for Enteric Diseases: the Scottish Encounter To Defeat Diarrheal Diseases. Clin Vaccine Immunol 23:272-81|
|Zhang, Yongrong; Feng, Hanping (2016) Pathogenic effects of glucosyltransferase from Clostridium difficile toxins. Pathog Dis 74:ftw024|
|DeLaine, BreOnna C; Wu, Tao; Grassel, Christen L et al. (2016) Characterization of a multicomponent live, attenuated Shigella flexneri vaccine. Pathog Dis 74:|
|Darton, Thomas C; Jones, Claire; Blohmke, Christoph J et al. (2016) Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Negl Trop Dis 10:e0004926|
|Yang, Zhiyong; Shi, Lianfa; Yu, Hua et al. (2016) Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection. Pathog Dis 74:|
|Maldarelli, Grace A; Matz, Hanover; Gao, Si et al. (2016) Pilin Vaccination Stimulates Weak Antibody Responses and Provides No Protection in a C57Bl/6 Murine Model of Acute Clostridium difficile Infection. J Vaccines Vaccin 7:|
|Toapanta, Franklin R; Bernal, Paula J; Fresnay, Stephanie et al. (2016) Oral Challenge with Wild-Type Salmonella Typhi Induces Distinct Changes in B Cell Subsets in Individuals Who Develop Typhoid Disease. PLoS Negl Trop Dis 10:e0004766|
|Galen, James E; Buskirk, Amanda D; Tennant, Sharon M et al. (2016) Live Attenuated Human Salmonella Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host Immunity. EcoSal Plus 7:|
Showing the most recent 10 out of 34 publications